Skip to main content
Log in

PK-PD modeling of irbesartan in healthy Chinese adult volunteers under non-steady-state conditions

  • Published:
European Journal of Drug Metabolism and Pharmacokinetics Aims and scope Submit manuscript

Summary

The purpose of this study was to construct a pharmacokinetic/pharmacodynamic model (PK-PD model) of irbesartan in healthy Chinese adult volunteers under non-steady-state conditions and provide relevant PK/PD parameters for use in clinical practice. Thirty-six healthy Chinese adult male volunteers received 150 or 300 mg irbesartan orally in tablet form (2 groups; n=18 per group). Plasma concentrations were determined by HPLC and pharmacological effects, including effects on systolic (SBP) and diastolic blood pressure (DBP) were measured simultaneously. The experimental data were quantitatively analyzed according to the PK-PD model construct. PK/PD parameters were calculated. Blood pressure remained almost unchanged at an irbesartan dose of 150 mg under non-steady-state conditions. After a single dose of 300 mg, the pharmacokinetic profiles of irbesartan conformed to a two-compartment model. There were hysteresis loops between drug effects and plasma concentrations. The relationship between effects and effect compartment concentrations (Ce) could be represented by the sigmoid-Emax model. The Emax values for the inhibitory effects on SBP and DBP of irbesartan were 14.8+1.5 and 9.8±2.1 mmHg respectively, the EC50 values were 0.29±0.11 and 0.18±0.07 μ.ml−1, while the Keo values were 0.62±0.09 and 0.68±0.07 h−1, respectively. The PK-PD model of irbesartan was developed in healthy Chinese adult male volunteers, and may provide a more rational basis for dosage individualization.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Waeber B. (2001 ): A review of irbesartan in antihypertensive therapy: comparison with other antihypertensive agents. Curr. Ther. Res. 62, 505–521.

    Article  CAS  Google Scholar 

  2. Mao G.G. Chen B. Sun H. et al (2001): Relative bioavailability of irbesartan capsules in healthy volunteers. Chin. J. Clin. Pharmacol. 17, 207–209.

    Google Scholar 

  3. Vachharajani N.N. Shyu W.C. et at (1998): Oral bioavailability and disposition characteristics of irbesartan, an angiotensin antagonist, in healthy volunteers. J. Clin. Pharmacol. 38, 702–707.

    CAS  PubMed  Google Scholar 

  4. Ismail Z. Triggs E.J. Smithurst B. A. et al (1989): The pharmacokinetics of amiloride hydrochlorothiazide combination in the young and elderly. Eur. J. Clin. Pharmacol. 37, 167–171.

    Article  CAS  PubMed  Google Scholar 

  5. Huang XH, Qiu FR, Xie HT, et al (2005): Pharmacokinetic and pharmacodynamic of irbesartan in renal hypertensive dogs under non-steady-state and steady-state conditions. Eur. J. Drug. Metab Pharmacokinet. 30, 121–125.

    CAS  PubMed  Google Scholar 

  6. Huang XH, Qiu FR, Xie HT et al (2005): Pharmacokinetic and pharmacodynamic interaction between irbesartan and hydrochlorothiazide in renal hypertensive dogs. J. Cardiovasc. Pharmacol. 46, 863–869.

    Article  CAS  PubMed  Google Scholar 

  7. Derendorf H, Meibohm B (1999): Modeling of pharmacokinetic/ pharmacodynamic (PK/PD) relationships: concepts and perspectives. Pharm. Res. 16, 176–177.

    Article  CAS  PubMed  Google Scholar 

  8. Collum WA (1981): Simultaneous pharmacokinetic and pharmacodynamic modeling. J. Pharmacokinet. Biopharm. 9, 367–388.

    Article  Google Scholar 

  9. Liu CX, Sun RY (1999): Experimental design and statistics of drug evaluation. Beijing: Military Medical Sciences Press. 64–66.

    Google Scholar 

  10. Meibohm B, Derendorf H (1997): Basic concepts of pharmacokinetic/ pharmacodynamic (PK/PD) modeling. Int. J. Clin. Pharmacol. Ther. 35, 401–413.

    CAS  PubMed  Google Scholar 

  11. Chen ZY, Zheng QS, Sun RY (2002): Introduction to the main functions of DAS pharmacological software. Chin. J. Clin. Pharmaco. Ther. 7, 562–564.

    Google Scholar 

  12. Huang XH, Li J (2005): Drug and statistics software. Am. J. Pharm. Educ. 69, 397–398.

    Google Scholar 

  13. Yin XX, Zhang YD, Luo JP (1997): Pharmacokinetic-pharmacodynamic modeling of metoprolol stereoisomers in spontaneously hypertensive rat. Acta. Pharmacol. Sinica. 18, 104–108.

    CAS  Google Scholar 

  14. Donati F, Varin F, Ducharme J, et al (1991): Pharmacokinetics and pharmacodynamics of atraccurium obtained with arterial and venous blood samples. Clin. Pharmacol. Ther. 49, 515–522.

    CAS  PubMed  Google Scholar 

  15. Fuseau E, Sheiner LB (1984): Commentary: simultaneous modeling of pharmacokinetics and pharmacodynamics with a nonparametric pharmacodynamic model. Clin. Pharmacol. Ther. 335, 733–741.

    Google Scholar 

  16. Shi SJ, Chen H, Gu SF, Zeng FD (2003): Pharmacokinetic pharmacodynamic modeling of daurisoline and dauricine in beagle dogs. Acta. Pharmacol Sin. 24, 1011–1015.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Huang, XH., Li, J., Qiu, FR. et al. PK-PD modeling of irbesartan in healthy Chinese adult volunteers under non-steady-state conditions. European Journal of Drug Metabolism and Pharmacokinetics 31, 259–264 (2006). https://doi.org/10.1007/BF03190465

Download citation

  • Received:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03190465

Keywords

Navigation